

Page 1 of 8

Version: 1.0 Issued: 13 Jun 2022

## 1. Identification

Product Identifier	Hydrocodone Bitartrate	
Other means of identification		
Internal item number	82393-0123	
CAS number	34195-34-1	
Synonyms	Dihydrocodeione bitartrate hydrate	
Chemical name	Morphinan-6-one, 4,5-epoxy-3-methoxy (R*,R*)]-2,3-dihydroxybutanedioate (1:1	
Relevant use and restrictions: No	o further information available.	
Application of substance: Active	pharmaceutical ingredient.	
Manufacturer/Supplier informatio	on	
Company name	Pharma Source Direct	
Address	8591 Prairie Trail Drive, Ste C-600	
	Englewood, CO 80112	
Website	www.pharmasd.com	
Emergency phone number	Infotrac: 1-800-535-5053	
2. Hazard(s) Identification		
Physical hazards	Not classified	
Health hazards	Acute toxicity, oral	Category 4
	Specific target organ toxicity, single exposure	Category 3 narcotic effects
OSHA defined hazards	Not classified	
Label elements	<b>^</b>	
Signal word	Warning	
Hazard statement	Harmful if swallowed. May cause drows	iness or dizziness.
Precautionary statement		
Prevention	Use only outdoors or in a well-ventilated handling. Do not eat, drink or smoke wh	
Response	If swallowed: Call a poison center/docto feel unwell. If inhaled: Remove person t comfortable for breathing. Call a poison professional. Rinse mouth.	o fresh air and keep
Storage	Store in a well-ventilated place. Keep co locked up.	ontainer tightly closed. Store
Disposal	Dispose of contents/container in accord local/regional/national/ international reg	



Version: 1.0 Issued: 13 Jun 2022

Hazards not otherwise classified (HNOC)

Safety Data

Sheet

Not classified.

### 3. Composition/Information on Ingredients

Substance			
Chemical name	Common name and synonyms	CAS number	%
Hydrocodone Bitartrate	Dihydrocodeione bitartrate hydrate	34195-34-1	100

4. First-aid Measures	
Inhalation	Move to fresh air. Call a POISON CENTER or doctor/physician if you feel unwell.
Skin contact	Rinse skin with water/shower. Get medical attention if irritation develops and persists.
Eye contact	Rinse with water. Get medical attention if irritation develops and persists.
Ingestion	Rinse mouth. IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell.
Most important symptoms/effects, acute and delayed	Narcotic effects.
Indication of immediate medical attention and special treatment needed	Treatment of opioid analgesic overdose should be symptomatic and supportive and may include the following: Do not induce vomiting. Administer activated charcoal as a slurry. Monitor vital signs, pulse oximetry, and cardiac function. Monitor for CNS and respiratory depression. For respiratory depression, administer oxygen and assist ventilation. Protect airway with orotracheal intubation. For coma and respiratory depression, reverse with naloxone. Administer intravenously, intramuscularly, intratracheally, intranasally, or subcutaneously. A continuous infusion might be needed for long- acting opioids. For seizures, treat with intravenous benzodiazepines. If seizures persist, administer propofol or barbiturates. For hypotension, treat with an infusion of isotonic fluid. If hypotension persists, administer dopamine or norepinephrine. Hemodialysis and hemoperfusion are not recommended. (Poisindex)
General Information	Remove from exposure. Remove contaminated clothing. For treatment advice, seek guidance from an occupational health physician or other licensed health-care provider familiar with workplace chemical exposures. In the United States, the national poison control center phone number is 1-800-222-1222. If person is not breathing, give artificial respiration. If breathing is difficult, give oxygen if available. Persons developing serious hypersensitivity (anaphylactic) reactions must receive immediate medical attention.

#### 5. Fire-fighting Measures

Water spray, dry chemical, carbon dioxide, or foam as appropriate for surrounding fire and materials.



Page 3 of 8

Version: 1.0 Issued: 13 Jun 2022

Unsuitable extinguishing media	None known.
Specific hazards arising from the chemical	No unusual fire or explosion hazards noted.
Special protective equipment and precautions for firefighters	Wear suitable protective equipment.
Fire fighting equipment/instructions	As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.
Specific methods	Use standard firefighting procedures and consider the hazards of other involved materials.

## 6. Accidental Release Measures

Safety Data

Sheet

Personal precautions, protective equipment and emergency procedures	Keep unnecessary personnel away. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Avoid inhalation of dust from the spilled material. Wear appropriate personal protective equipment.
Methods and materials for containment and cleaning up	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid the generation of dusts during clean-up. For waste disposal, see section 13 of the SDS. Wash spill site.
7. Handling and Storage	

Precautions for safe handling	As a general rule, avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Clean equipment and work surfaces with suitable detergent or solvent after use. After removing gloves, wash hands and other exposed skin thoroughly. Use of a designated area is recommended for handling of potent materials.
Conditions for safe storage, including any incompatibilities	Store in tight container. This material should be handled and stored per label instructions to ensure product integrity.

# 8. Exposure Controls & Personal Protection

# Exposure limit values

Ind	dus	tri	al	Us	е
	JUS		a	υa	

Material	Туре	Value
Hydrocodone Bitartrate (CAS 3419	95-34-1) STEL	100 micrograms/m3
	TWA	33 micrograms/m3
Biological limit values	No biological exposure limit	ts noted for the ingredient(s)
Appropriate engineering controls	controls such as general di or process enclosure. Loca to general exhaust because source, preventing dispersi survey involving air monitor effectiveness of engineering	be controlled primarily by engineering lution ventilation, local exhaust ventilation, I exhaust ventilation is generally preferred e it can control the contaminant at its on into the work area. An industrial hygiene ring may be used to determine the g controls. Effectiveness of engineering ith highly potent materials should be ic surrogate materials.



Page 4 of 8

Version: 1.0 Issued: 13 Jun 2022

	Local exhaust ventilation such as a laboratory fume hood or other vented enclosure is recommended, particularly for grinding, crushing, weighing, or other dust-generating procedures.
Individual protection measures, such	n as personal protective equipment
Eye/face protection	Safety glasses with sideshields are recommended. Face shields or goggles may be required if splash potential exists or if corrosive materials are present. Approved eye protection (e.g., bearing the ANSI Z87 or CSA stamp) is preferred. Maintain eyewash facilities in the work area.
Skin protection	
Hand protection	Chemically compatible gloves. For handling solutions, ensure that the glove material is protective against the solvent being used. Use handling practices that minimize direct hand contact. Employees who are sensitive to natural rubber (latex) should use nitrile or other synthetic nonlatex gloves. Use of powdered latex gloves should be avoided due to the risk of latex allergy.
Other	For handling of laboratory scale quantities, a cloth lab coat is recommended. Where significant quantities are handled, work clothing may be necessary to prevent take-home contamination.
Respiratory protection	Where respirators are deemed necessary to reduce or control occupational exposures, use NIOSH-approved respiratory protection and have an effective respirator program in place (applicable U.S. regulation OSHA 29 CFR 1910.134).
Thermal hazards	Not available.
General hygiene considerations	Handle in accordance with good industrial hygiene and safety practice.

0 Devoiced and Chemical Properties	
9. Physical and Chemical Properties	

Safety Data Sheet

Appearance	Fine, white crystals or crystalline powder.
Physical state	Solid.
Form	Powder.
Odor	Odorless.
Odor threshold	Not available.
рН	3.2 - 3.8 (2% solution)
Melting point/freezing point	244.4 - 262.4 °F (118 - 128 °C) ; also reported as 194 - 198 °C
Initial boiling point and boiling range	Not available.
Flash point	Not available.
Evaporation rate	Not available.
Flammability (solid, gas)	Not applicable.
Upper/lower flammability or explosition in the second second second second second second second second second s	ve
Flammability limit - lower (%)	Not available.
Flammability limit - upper (%)	Not available.
Explosive limit - lower (%)	Not available.
Explosive limit - upper (%)	Not available.



Version: 1.0 Issued: 13 Jun 2022

Page 5 of 8

Vapor pressure	< 0.0000001 kPa (77 °F (25 °C))
Vapor density	Not available.
Relative density	Not available.
Solubility in water	Soluble.
Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
Other information	
Chemical family	Morphinan derivative; phenanthrene derivative.
Molecular formula	C18H21NO3 . C4H6O6 . 2 1/2H2O
Molecular weight	494.49
Solubility (other)	Slightly soluble in ethanol; insoluble in ether and in chloroform.

#### 10. Stability and Reactivity

Sheet

Reactivity	No reactivity hazards known
Chemical stability	Stable at normal conditions.
Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
Conditions to avoid	None known.
Incompatible materials	Oxidizing agents. Alkalis. Strong acids. Heavy metal salts.
Hazardous decomposition products	NOx. Irritating and/or toxic fumes or gases. Emits toxic fumes under fire conditions.

# 11. Toxicological Information

## Information on likely routes of exposure

Inhalation Skin contact Eye contact Ingestion	Harmful if swallowed. Due to lack of data the classification is not possible. Due to lack of data the classification is not possible. Due to lack of data the classification is not possible.
Symptoms related to the physical, chemical, and toxicological characteristics	Opioid analgesics: Dizziness. Drowsiness. Weakness. Restlessness. Euphoria. Depression. Agitation. Confusion. Hallucinations. Slurred speech. Nausea. Vomiting. Constipation. Decreased or difficult urination. Sweating. Flushing. Itching. Rash. Drowsiness. Cold and clammy skin. Difficulty breathing. Loss of consciousness. Pinpoint pupils. Muscle rigidity. Convulsions. Seizures.
Delayed and immediate effects of exposure	Opioid analgesics: Mood or mental changes. Low blood pressure. Slow or irregular heart rate. Hypothermia. Coma. Heart attack. Death.
Chronic effects	Opioid analgesics: Tolerance. Dependence.



Page 6 of 8

Version: 1.0 Issued: 13 Jun 2022

Medical conditions aggravated by exposure	Opioid analgesics: Liver impairment. Kidney impairment. Hypothyroidism. Seizure disorders. Asthma. Respiratory disorders. Heart arrhythmia. Alcoholism. History of drug abuse or dependence. Gallbladder disorders. Inflammatory bowel disease. Urinary disorders. Low blood pressure. Gastrointestinal obstruction. Adrenal gland problems. Sickle cell disease. Addison's disease. Concurrent use of monoamine oxidase inhibitors (MAOIs).	
Acute toxicity	Harmful if swallowed.	
Product	Species	Test Results
Hydrocodone Bitartrate (CAS 34195-34	1-1)	
Oral		
LD50	Rat	375 mg/kg, (anhydrous)
Skin corrosion/irritation	Due to lack of data the classification	is not possible.
Serious eye damage/eye irritation	Due to lack of data the classification	is not possible.
Respiratory sensitization	Due to lack of data the classification is not possible.	
Skin sensitization	Due to lack of data the classification	is not possible.
Germ cell mutagenicity	Based on available data, the classific	cation criteria are not met.
Mutagenicity		
Ames S. typhimurium mi Result: Negative. Basc test in Drosophila g Result: Negative. Micronucleus test in mou Result: Negative.	jerm cells	
Carcinogenicity	Due to lack of data the classification This product is not considered to be NTP, or OSHA.	
Reproductive toxicity	Based on available data, the classific opioids during pregnancy may cause leading to respiratory difficulties and (dehydration, irritability, tremors, exc newborn. Epidemiological studies have not sho therapeutic use of this material durin incidence of birth defects. Reproductivity studies in animals have	e physical dependence in the fetus withdrawal symptoms æssive crying, diarrhea) in the own an association between g pregnancy and an increased
Specific target organ toxicity - single exposure	Narcotic effects.	
Specific target organ toxicity - repeated exposure	Based on available data, the classific	cation criteria are not met.
Aspiration hazard	Based on available data, the classific	cation criteria are not met.

12. Ecological Information	
Ecotoxicity	No ecotoxicity data noted for the ingredient(s).
Persistence and degradability	No data is available on the degradability of this product.



Page 7 of 8

Version: 1.0 Issued: 13 Jun 2022

Bioaccumulative potential
Mobility in soil
Other adverse effects

Not available. Not available. Not available.

13. Disposal Considerations		
Disposal instructions	Dispose of contents/container in accordance with local/regional/national/international regulations.	
Local disposal regulations	Not available.	
Hazardous waste code	Not regulated.	
Waste from residues / unused products	Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see:	

Contaminated packagingDisposal instructions).Contaminated packagingEmpty containers should be taken to an approved waste handling site<br/>for recycling or disposal. Since emptied containers may retain product<br/>residue, follow label warnings even after container is emptied.

#### 14. Transport Information

### DOT

Not regulated as dangerous goods.

# IATA

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code	No information available.
General information	It is the shipper's responsibility to determine the correct transport classification at the time of shipment.

### 15. Regulatory Information

US federal regulations	CERCLA/SARA Hazardous Substances - Not applicable.
	One or more components are not listed on TSCA.
Superfund Amendments and Reaut	horization Act of 1986 (SARA)
Hazard categories	Immediate Hazard - Yes Delayed Hazard - Yes Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No
SARA 302 Extremely hazardous substance SARA 311/312 Hazardous chemical	No



Safety Data

Sheet

Version: 1.0 Issued: 13 Jun 2022

Othe	er federal regulations		
	Safe Drinking Water Act (SDWA)	Not regulated.	
	y Enforcement Administration λ) (21 CFR 1308.11-15)	Schedule II - 9193	
US s	tate regulations	California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins.	
Inter	national Inventories		
	Country(s) or region	Inventory name	On inventory (yes/no)*
	Australia	Australian Inventory of Chemical Substances (AICS)	No
	Canada	Domestic Substances List (DSL)	No
	Canada	Non-Domestic Substances List (NDSL)	No
	China	Inventory of Existing Chemical Substances in China (IECSC)	No
	Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
	Europe	European List of Notified Chemical Substances (ELINCS)	No
	Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
	Korea	Existing Chemicals List (ECL)	No
	New Zealand	New Zealand Inventory	No
	Phillipines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No
	Unites States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

\*A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other Information		
Disclaimer	The information in this SDS has been compiled from sources considered dependable, but has not been independently verified. The company cannot guarantee the accuracy of information herein, and the statements contained should not be considered an official expression. The company will not assume liability for any loss, damage, and/or expense resulting from the use and/or misuse of this product in regards to handling, storage, and/or disposal.	
Issue date	13 Jun 2022	
Version	1.0	
Issued by	Pharma Source Direct – Quality Assurance	